CN120081826A - 吡咯烷化合物的晶体 - Google Patents

吡咯烷化合物的晶体 Download PDF

Info

Publication number
CN120081826A
CN120081826A CN202510224370.1A CN202510224370A CN120081826A CN 120081826 A CN120081826 A CN 120081826A CN 202510224370 A CN202510224370 A CN 202510224370A CN 120081826 A CN120081826 A CN 120081826A
Authority
CN
China
Prior art keywords
crystals
crystal
pyrrolidine
phosphoric acid
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510224370.1A
Other languages
English (en)
Chinese (zh)
Inventor
上田直子
长田裕臣
吉田琢纮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of CN120081826A publication Critical patent/CN120081826A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202510224370.1A 2018-12-28 2019-12-27 吡咯烷化合物的晶体 Pending CN120081826A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2018-247437 2018-12-28
JP2018247437 2018-12-28
CN201980086473.9A CN113226314B (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体
PCT/JP2019/051570 WO2020138481A1 (ja) 2018-12-28 2019-12-27 ピロリジン化合物の結晶

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980086473.9A Division CN113226314B (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体

Publications (1)

Publication Number Publication Date
CN120081826A true CN120081826A (zh) 2025-06-03

Family

ID=71127176

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202510224370.1A Pending CN120081826A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体
CN201980086473.9A Active CN113226314B (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体
CN202510225181.6A Pending CN120081827A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201980086473.9A Active CN113226314B (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体
CN202510225181.6A Pending CN120081827A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体

Country Status (8)

Country Link
US (2) US12077524B2 (cg-RX-API-DMAC7.html)
EP (4) EP3903785B1 (cg-RX-API-DMAC7.html)
JP (3) JP6977185B2 (cg-RX-API-DMAC7.html)
CN (3) CN120081826A (cg-RX-API-DMAC7.html)
ES (1) ES2991904T3 (cg-RX-API-DMAC7.html)
MA (1) MA54619A (cg-RX-API-DMAC7.html)
TW (3) TWI834791B (cg-RX-API-DMAC7.html)
WO (1) WO2020138481A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR122595A1 (es) 2020-06-10 2022-09-21 Mitsubishi Tanabe Pharma Corp Agente profiláctico o terapéutico para fotodermatosis
KR102952931B1 (ko) 2020-06-10 2026-04-15 다나베 파마 가부시키가이샤 포르피린증의 예방 또는 치료제
CN122557552A (zh) * 2020-06-10 2026-08-14 田边制药株式会社 卟啉症的预防或治疗剂
CN117255786A (zh) * 2021-05-06 2023-12-19 株式会社Lg 化学 黑皮质素受体激动剂化合物的晶型vii及其制备方法
KR102854595B1 (ko) * 2021-05-06 2025-09-03 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 결정형 v 및 이의 제조방법
KR102854598B1 (ko) * 2021-05-07 2025-09-03 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 황산염의 결정형 및 이의 제조방법
JP2024517271A (ja) * 2021-05-07 2024-04-19 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の有機酸塩の結晶形ivおよびその製造方法
US20240239769A1 (en) * 2021-05-07 2024-07-18 Lg Chem, Ltd. Co-crystal of melanocortin receptor agonist compound and vanillin and method for preparing same
KR20240145490A (ko) 2022-01-31 2024-10-07 미쓰비시 타나베 파마 코퍼레이션 멜라노코르틴 1 수용체 아고니스트의 신규 용도
WO2024029599A1 (ja) 2022-08-03 2024-02-08 田辺三菱製薬株式会社 1-{2-[(3s,4r)-1-{[(3r,4r)-1-シクロペンチル-3-フルオロ-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-4-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸もしくはその医薬的に許容し得る塩又は共結晶を含有する医薬組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
EP1951286A4 (en) * 2005-10-07 2009-11-04 Waratah Pharmaceuticals Inc COMBINED USE OF INHIBITORS OF DPP-IV AND GASTRIN COMPOUNDS
PT3150578T (pt) * 2014-05-29 2021-01-18 Mitsubishi Tanabe Pharma Corp Novo composto de pirrolidina e aplicação como agonista do recetor de melanocortina
JP6392297B2 (ja) * 2015-11-27 2018-09-19 田辺三菱製薬株式会社 医薬組成物

Also Published As

Publication number Publication date
ES2991904T3 (es) 2024-12-05
TWI919623B (zh) 2026-03-21
MA54619A (fr) 2021-11-03
CN120081827A (zh) 2025-06-03
JP2025085744A (ja) 2025-06-05
WO2020138481A1 (ja) 2020-07-02
JP7652682B2 (ja) 2025-03-27
EP3903785A4 (en) 2022-08-10
EP4603143A3 (en) 2025-11-05
EP4603143A2 (en) 2025-08-20
EP3903785A1 (en) 2021-11-03
TWI870228B (zh) 2025-01-11
TW202039464A (zh) 2020-11-01
CN113226314A (zh) 2021-08-06
TW202421621A (zh) 2024-06-01
JPWO2020138481A1 (ja) 2021-09-27
EP3903785B1 (en) 2024-10-02
EP4434582A3 (en) 2024-12-18
US12077524B2 (en) 2024-09-03
TW202517631A (zh) 2025-05-01
JP2022024034A (ja) 2022-02-08
TWI834791B (zh) 2024-03-11
EP4434582A2 (en) 2024-09-25
JP6977185B2 (ja) 2021-12-08
US20250002474A1 (en) 2025-01-02
CN113226314B (zh) 2025-03-18
EP4763282A2 (en) 2026-06-24
US20220073497A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
CN113226314B (zh) 吡咯烷化合物的晶体
US10023577B2 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
US8501753B2 (en) Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-D] pyrimidin-4-one
EP3205653B1 (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
US20090076272A1 (en) Polymorphs of eszopiclone malate
JP2026012851A (ja) ノボビオシン類似体とプロリンとの共結晶形態
JP2024525254A (ja) ウロデシン塩
WO2023061372A1 (zh) 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途
HK40130190A (en) Crystal of pyrrolidine compound
JP2017530107A (ja) ナトリウム・グルコース共輸送体2阻害薬のl−プロリン化合物、およびl−プロリン化合物の一水和物および結晶
JP2015534989A (ja) {s−3−(4−アミノ−1−オキソ−イソインドリン−2−イル)(ピペリジン−3,4,4,5,5−d5)−2,6−ジオン}の固体形態
JP2015536316A (ja) L‐リジンを含む(3s,3s’)4,4’‐ジスルファンジイルビス(3‐アミノブタン1‐スルホン酸)の新規結晶相
CN116178277A (zh) 氯比普兰甲磺酸盐晶型及其制备方法
WO2026037326A1 (zh) 吡啶酰胺类化合物的盐和晶型及其制备方法
JP2021505602A (ja) 腎外髄質カリウムチャネル阻害剤の結晶形およびその調製方法
BRPI0904938A2 (pt) método de obtenção de um co-cristal de lamivudina, seu sal maleato, formulações farmacêuticas e seu uso

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination